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Background: Cryotherapy is the most common non-pharmacological pain-relieving method. The aim of this pilot
study was to ascertain whether intranasal evaporative cooling may be an effective intervention in an acute migraine
attack. Studies have previously demonstrated effectiveness of a variety of cryotherapy approaches. Intranasal
evaporative cooling due to vascular anatomy, allows the transfer of venous blood from nasal and paranasal mucous
membranes to the dura mater, thereby providing an excellent anatomical basis for the cooling processes.
Methods: We conducted a prospective, open-label, observational, pilot study. Twenty-eight patients who satisfied
the International Classification of Headache Disorders (ICHD 2) diagnostic criteria for migraine were recruited. A total
of 20 treatments were administered in 15 patients. All patients provided pain severity scores and migraine-associated
symptoms severity scores (based on a 0–10 visual analogue scale, [VAS]).
Results: Out of the 20 treatments, intranasal evaporative cooling rendered patients’ pain and symptoms free
immediately after treatment, in 8 of the treatments (40%), a further 10 treatments (50%) resulted in partial pain relief
(headache reduced from severe or moderate to mild) and partial symptoms relief. At 2 hours, 9 treatments (45%)
provided full pain and symptoms relief, with a further 9 treatments (45%) resulting in partial pain and symptoms relief.
At 24 hours, 10 treatments (50%) resulted in patients reporting pain and symptom freedom and 3 (15%) provided
partial pain relief. In summary 13 patients (87%) had benefit from the treatment within 2 hours that was sustained at
24 hours.
Conclusions: Intranasal evaporative cooling gave considerable benefit to patients with migraine, improving headache
severity and migraine-associated symptoms. A further randomised, placebo controlled, double blinded, parallel clinical
trial is required to further investigate the potential of this application.
Trial registration: Clinicaltrials.gov registered trial, ClinicalTrials.gov Identifier: NCT01898455.
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Mechanical techniques to alleviate migraine symptoms
have been used for many years, cooling and compression
being the most frequently applied. Cryotherapy is the
most common non-pharmacological self-administered
pain-relieving method currently used by migraine suf-
ferers [1]. The first manuscript documenting the applica-
tion of ice mixtures was published by James Arnott in
1849 [2]. Simple techniques based on cryotherapy, using
various methods of cold and ice application have been* Correspondence: jitka.vanderpol@cumbria.nhs.uk
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in any medium, provided the original work is preported over the last three decades [3-6]. Friedman [7]
described a device using hollow metal tubes cooled by
circulating cold water, applied to the periapical area of
the maxillary molars. Sprouse-Blum [8] reported benefit
from applying frozen icepacks targeting carotid arteries
at the front of the neck in migraine treatment.
Several pathophysiological mechanisms of action have
been proposed. These mechanisms include:
1. Neurovascular mechanism: Application of cold
induces vasoconstriction with subsequent decreased
downstream blood flow [9,10]. This leads to
inhibition of the release of inflammatory mediatorsis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 RhinoChill© Intranasal cooling system: A/schematic,
B/picture of the device and intranasal catheter. Nasal catheter
inserted into the patient’s nostrils, coolant driven by oxygen
evaporates within the nasopharynx.
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local oedema [11,12].
2. Pain gating by differential effect on nerve conduction:
Cryotherapy induces analgesia by slowing nerve
conduction velocity, with small myelinated fibers
being affected first, followed by large myelinated
fibers and the unmyelinated fibers being affected last
[13,14]. Via mechanism of the gate control of pain,
affecting the small myelinated nociceptive pain
afferents first, cryotherapy induces analgesia [15,16].
3. Metabolic mechanism: Cryotherapy decreases
metabolic and enzymatic activity, due to reduced
demand for adenosine triphosphate (ATP) and
oxygen [17].
4. Transient Receptor Potential (TRP) channels: Recent
studies suggest that TRP channels may have a role
in headache and pain genesis due to their response
to environmental stimuli such as temperature
changes [18].
The nasopharynx provides a large diffuse surface area
that is highly vascular. Cooling via the nasopharynx
therefore offers the ability to cool across the thin cribri-
form plate via both direct conductive mechanisms that
do not rely on spontaneous circulation as well as indirect
haematogenous mechanisms. Numerous subarachnoid
and pial arterial branches exposed to the cerebrospinal
fluid (CSF) have diameters in the range of the vessels of
the retia mirabilia of animals in which selective brain cool-
ing has been clearly established experimentally [19]. Vas-
cular anatomy allows transfer of venous blood from the
skin of the head as well as nasal and paranasal mucous
membranes to the dura mater [20] thereby providing an
excellent basis for the convective process of intranasal
evaporative cooling. The dura mater, with its high vas-
cularization, may transmit temperature changes to the
CSF compartment, which may influence the temperature
of brain parenchyma directly or indirectly, via brain
arteries.
The aim of this study was to ascertain whether intra-
nasal evaporative cooling might be an effective and safe
intervention in acute migraine treatment.
Methods
Study design
This study is an investigator-initiated clinical trial, inves-
tigating the effectiveness of the RhinoChill© intranasal
cooling system for the acute relief of migraine in an
adult population, through short periods of intranasal
cooling.
We conducted a single-centre, prospective, open-label,
observational, pilot study. Participants were enrolled
from October 2013 to July 2014, from the outpatient
clinics of the Neurology Department, Cumbria PartnershipNHS Trust, and through a community engagement adver-
tising campaign.
Study design consisted of a screening visit or phone
call, baseline visit, minimum of one treatment and a
follow-up phone call at 2 and 24 hours after each treat-
ment. The principle of the intranasal cooling, procedure
and safety aspects of the intervention were explained to
each of the participants.
Patient recruitment
The study participants were otherwise healthy adults
who met ICHD 2 diagnostic criteria for episodic mi-
graine with or without aura, or chronic migraine and
were capable of giving informed consent. Exclusion cri-
teria included history of any current co-morbid illness
or difficulty with insertion of the nasal cannula due to
congenital anatomical narrowing of the nasal passages.
Trial device
The RhinoChill© Intranasal cooling device is a portable
unit consisting of a control unit, a disposable nasal cath-
eter and a 1-liter bottle of coolant. The device requires a
supply of oxygen or medical air to drive the evaporation
process of the coolant. The 10 cm long intranasal cathe-
ters have spray ports on the dorsal surface to distribute
coolant into the nasal cavity, upwards towards the base
of the skull (Figure 1).
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chain perfluorocarbon. PFH is a colorless, odourless,
radiolucent liquid. PFH belongs to a class of perfluoro-
carbon fluids that are fully fluorinated with no functional
reactive groups. They do not oxidize or hydrolyze and
are thus chemically and biologically inert. They cannot
undergo biological oxidation-reduction reactions to form
reactive aldehydes, acid fluorides, radicals, or other acids.
Since PFH does not react directly with biological tissue,
they can form no reactive metabolites. PFH surface ten-
sion is lower than water so it will spread uniformly and
quickly throughout the space in which it is sprayed. These
properties facilitate RhinoChill coolant dispersion to the
large diffuse surface area of the nasal cavity to maximize
cooling.
Evaporation of the coolant provides rapid cooling to
the nasal cavity of approximately 2°C, absorbing heat
through evaporation and cooling local structures through
direct conductive mechanisms and indirect haematogen-
ous mechanisms. Safety of the device has been established
in the cardiac arrest population where it has been used to
induce rapid brain cooling for therapeutic hypothermia as
neuroprotection [21,22]. In this study, the device was only
used on its lowest setting of ‘Low’ flow rate and for a max-
imum duration of 20 minutes as it was not the intention
to induce therapeutic hypothermia.
Therapeutic regimen
This trial was a feasibility study. To ensure patient
safety, participants attended the hospital Day Case Unit
during a migraine attack, to obtain their treatment
under medical supervision. At onset of a migraine at-
tack, the patient would contact the trial researcher and
come into the hospital for treatment. On arrival, baseline
observations were taken including infrared tympanic
thermometry, non-invasive blood pressure (NIBP), pulse
and oxygen saturation. Migraine pain severity was assessed
using a visual analogue scale (VAS, 0–10 with 0 being pain
free and 10 very severe pain), which was extrapolated to
provide a categorical scale of pain intensity using the
Glaxo-scale of Severe, Moderate, Mild and None. The use
of both scales allow for comparison with other published
literature regarding non-pharmaceutical and pharmaceut-
ical approaches to acute migraine treatment. The associ-
ated migraine symptoms (nausea, vomiting, photophobia,
visual symptoms, face asymmetry, neck pain/stiffness and
numbness/weakness in extremities) were also scored using
VAS, whereby the patient provided a subjective composite
score regarding the overall severity of their combined as-
sociated symptoms.
Following confirmation of an acute migraine attack,
treatment was commenced. Lubricated nasal cannulae
were inserted into both nostrils. If full insertion proved
intolerable then a shallow insertion only (as far astolerable - ¼, ½ or ¾ of the cannula) was completed. A
maximum of 20 minutes of cooling was provided with
predetermined early stoppage if there was full relief of
pain or at the participant’s request due to discomfort.
Migraine pain severity score, tympanic thermometry
and NIBP, as well as pain and discomfort associated with
the cooling device, was measured every 5 minutes
throughout the treatment. Immediately after treatment
was terminated, 2 hours post treatment and at 24 hours
after treatment, pain severity and migraine-associated
symptom composite scores were recorded. The partici-
pants were required to stay within the unit for a mini-
mum of 1 hour following their treatment as a safety
precaution. The patient was then phoned at 2 hours to
enable recording of a migraine pain and symptom sever-
ity score.
The primary endpoint for this study was the reduction
of pain and associated symptoms from baseline assessment,
just after the treatment, at 2 and 24 hours post-treatment.
Secondary endpoints were tolerance to RhinoChill cool-
ing during treatment, pain and discomfort levels due to
the cooling procedure itself, and adverse events noted
throughout the treatment phase and during follow up.
Statistical analyses
Data were analyzed using SPSS version 20.0 using paired
sample T-test and the χ2 test, where p < 0.05 would be
considered significant. Shapiro-Wilks and Friedman’s
non-parametric test were used to test the validity of the
pain and symptom severity VAS scores.
Ethics or institutional review board approval
The study protocol was approved by the NRES Commit-
tee North West - Lancaster Ethics Committee. This
study is registered at clinicaltrials.gov (NCT01898455).
All participants provided written consent before taking
part.
Study protocol
Trial registration: Clinicaltrials.gov registered trial, Clinical-
Trials.gov Identifier: NCT01898455.
Results
Data are presented as an extended case series with quali-
tative data to support the acceptability aspects of the
nasal cooling in migraine treatment. Data analysis was
performed ‘per treatment’ due to the variation of treat-
ment numbers received by the patients in the trial. How-
ever, overall treatment response per patient is also
described.
Demographic data
Twenty-eight adult patients were recruited into the trial
of whom 15 patients received one or more treatments,
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single treatment, while 3 patients had 2 treatments and
1 patient had 3. All patients were reviewed on entry to
the clinic when they attended for treatment and asked
about their current frequency of migraines. The most
common reasons for lack of repeated treatments was
due to migraines occurring outside of the operating
hours of the trial, as well as inability to travel due to
severity of migraine, not being able to leave work and
having difficulty with childcare arrangements. The 13
patients who did not receive a treatment stated that they
had migraines at times that were out-of-hours offered by
the trial centre. The cohort comprised 12 (80%) female
and 3 (20%) male patients, with mean age of 43 years
(range 29–66 years). When asked about the normal dur-
ation of headache with standard medication and treat-
ments, 14 (93%) patients stated that their headaches
usually lasted longer than 24 hours after onset (Table 1).
Headache severity and migraine-associated symptom
severity score
All patients provided pain severity scores as well as a
migraine-associated symptoms severity scores (single
composite score) based on the visual analogue scale.
This occurred on arrival to the department, throughout
the treatment, immediately at the end of the treatment,
at 2 and 24 hour post treatment. Results for pain scores
and migraine-associated symptom severity scores are
shown in Figures 2 and 3 and Tables 2 and 3.
Out of the 20 treatments provided to patients in this
trial, intranasal evaporative cooling rendered patients’
pain and symptoms free immediately after treatment inTable 1 Patient migraine characteristics
Pt no. Age Sex Time since migraine
diagnosis
Migraine t
002 58 F 9 Years Episodic M
003 41 F 25 Years Chronic Mi
004 66 M 29 Years Chronic Mi
005 43 F 34 Years Episodic M
006 29 F 9 Years Episodic M
007 42 F 3.5 Years Chronic Mi
009 33 M 17 Years Chronic Mi
010 57 F 4 Years Episodic M
012 36 F 2 Years Chronic Mi
013 50 F 30 Years Episodic M
015 42 F 2 Years Episodic M
016 47 F 9 Years Episodic M
017 33 F 20 Years Episodic M
022 37 M 9 Years Chronic Mi
023 30 F 4 Years Chronic Mi
VAS, visual annalogue scale.8 of the treatments (40%). A further 10 treatments (50%)
resulted in partial pain relief (headache reduced from se-
vere or moderate to mild) and partial symptoms relief.
At 2 hours, 9 treatments (45%) provided full pain and
symptoms relief with a further 9 treatments (45%) result-
ing in partial pain and symptoms relief. At 24 hours, 10
treatments (50%) resulted in patients reporting pain and
symptom freedom. Of those treatments remaining, 3
(15%) provided partial pain relief. Relapse of migraine
after a period of relief occurred in 5 (25% of treatments).
Two treatments (10%) did not respond to intranasal
cooling.
When examining data on a ‘per patient’ basis rather
than ‘per episode’, using mean scores for those patients
who had one or more treatments and with the classifica-
tion of treatment response as being a reduction in pain
severity from severe/moderate to mild/none 13 patients
(87%) had a positive treatment response to Intra-nasal
cooling at two hours post-treatment that was sustained
at 24 hours.
Comparing the group of patients suffering from chronic
migraine (n = 7) with episodic migraine (n = 8), no differ-
ence was seen in treatment response rate albeit that the
small numbers involved do not allow any firm conclusions
to be drawn on any differences that there may be between
treatment response in episodic and chronic migraine
patients.
Reduction in both pain severity score and migraine-
associated symptom severity score from baseline to each
time point was statistically significant (p ≤ 0.001) repre-
senting a consistent downward trend in both pain and




igraine without aura 24 – 48 hours 9
graine 48 – 72 hours 10
graine 24 – 36 hours 9
igraine without aura 24 – 72 hours 9
igraine without aura 12-72 hours 6
graine <12 hours 7.5
graine 24 – 36 hours 3 – 9
igraine without aura 24 – 72 hours 7
graine 48 – 72 hours 10
igraine with aura 48 – 72 hours 3 – 8
igraine with aura 36 – 48 hours 8
igraine with aura 24 – 48 hours 10
igraine without aura 24 – 36 hours 8 – 9
graine 48 – 72 hours 7
graine 48 – 72 hours 5 – 10
Figure 2 Pain severity score (VAS 0-10). p values correspond to comparison of pain severity score over time against baseline score. VAS:
0 = no pain/no discomfort, 10 = severe pain/discomfort. Tx = treatment.
Figure 3 Migraine-associated symptoms severity score (VAS 1–10). p values correspond to comparison of symptom severity score over time
against baseline score. VAS: 0 = no pain/no discomfort, 10 = severe pain/discomfort; Tx, Treatment.
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Table 2 Pain severity scores
Time Number Pain severity measured
using VAS (0–10)
Mean (±SD) Range
On admission 20 5.98 (±1.84) 1-10
After 5 mins of treatment 20 4.28 (±2.62) 0-10
After 10 mins of treatment 20 3.79 (±2.81) 0-10
Immediately after treatment 20 3.13 (±2.73) 0-10
2 Hours post-treatment 20 2.43 (±2.28) 0-8
24 hours post-treatment 20 1.98 (±2.71) 0-9
VAS, visual analogue score; SD, standard deviation.
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of the pain and symptom severity VAS scores. For the
pain and symptom severity score the distribution be-
came less normal over time as the scores tended towards
zero (as can be seen from the median values in Tables 2
and 3). To take this into account a Friedman’s non-
parametric repeated measures test was used, where the
overall statistics showed a significant effect. A series of
Wilcoxon repeated measures test were calculated com-
paring scores on admission to scores immediately after
treatment, 2 hours after treatment and 24 hours after
treatment. Table 4 shows a significant overall effect for
both Pain Severity Score and Symptom Severity Score,
with all subsequent pairwise comparisons against the
score on admission found to be significant.
Tolerance of intranasal cooling
Patients provided visual analogue scores during the ap-
plication of Intranasal cooling to describe any pain and/
or discomfort associated with the cooling process itself,
independent of migraine pain and associated symptoms
scores. Mean scores are presented in Figure 4 and
Table 5. Shallower insertions were associated with less
pain and discomfort. Patients also rated benefits of the
intranasal cooling compared to discomfort or pain asso-
ciated with the treatment. Two patients (13%) reported
that the discomfort/pain outweighed any benefit deliv-
ered. Thirteen patients (87%) would use the treatment if
available outside of the trial and 2 (13%) would not. Fur-
thermore, when asked how Intranasal cooling comparedTable 3 Migraine-associated symptoms severity scores
Time Number Migraine-associated
symptoms severity score
measured using VAS (0–10)
Mean (±SD) Range
On admission 20 4.25 (±2.37) 0-9
Immediately after treatment 20 1.90 (±1.83) 0-6
2 Hours post-treatment 20 0.90 (±1.24) 0-3.5
24 hours post-treatment 20 0.70 (±1.38) 0-5
VAS, visual analogue score; SD, standard deviation.to current rescue medication taken, 9 patients (60%)
stated that intranasal cooling was better, 4 (26%) stated
the response was as good as their current medication
and 2 (14%) felt that their current rescue therapies
worked better than the intranasal cooling.
Tympanic temperature
Due to the use of a short duration low flow treatment
with the RhinoChill device, we did not note decrease in
tympanic temperature after a maximum of 20 minutes
of intranasal cooling on a low flow setting (36.65°C base-
line v 36.60°C post treatment. p = 0.485).
Mean arterial blood pressure
When looking at mean arterial pressure across all treated
migraine episodes (n = 20), the difference between base-
line mean arterial pressure (MAP) and 10 minutes into
treatment as well as baseline MAP and immediately after
treatment are both significantly different (Baseline v 10
mins, p = <0.001; Baseline v immediately after treatment,
p = 0.04). As catheter insertion depth is decreased, the dif-
ference between MAP readings also starts to decrease
(Figure 5). MAP for patients who had an insertion depth
of ¼ to ¾ of the nasal catheter (n = 14) remained signifi-
cant when comparing baseline to 10 minutes of treatment
(p = 0.02) but became non-significant when comparing to
immediately after treatment (p = 0.32). Finally, when
examining data from those patients who had only a ¼ or
½ insertion (n = 11), there is no difference between base-
line and 10 minutes of treatment (p = 0.147) or immedi-
ately following treatment (p = 0.78).
Adverse events
Adverse events recorded are listed in Table 6. During the
treatment nasal discomfort and pain due to catheter was
reported in 3 treatments, nasal discomfort due to cooling
was reported in 2 treatments, mild epistaxis (blood streaks
reported in 1 case), and excess coolant dripping from nose
was reported during 2 treatments. Hypertension was
noted in one patient on two consecutive treatments within
10 minutes of starting intranasal cooling with a full depth
insertion of the nasal catheter (increase of NIBP from
146/88 to 192/111 – treatment 1; and from 141/82 to
184/102 – treatment 2). At the time of measurement, this
patient scored a high pain and discomfort score associated
with the catheter placement. Treatment was discontinued
early in one case. Blood pressure immediately decreased
following treatment and returned to baseline within 1 hour
following treatment. Following this patient’s experience,
further treatments were offered with a shallower insertion,
either ¾, ½, or ¼ depth depending on patient comfort. No
further episodes of hypertension were recorded once shal-
lower insertions were delivered.
Table 4 Shapiro–Wilks and Friedman’s tests on pain scores and migraine-associated symptom scores


























Pain Score 5.9(1.8) 6(5–7) 3.1(2.7) 3(0.6–5) 2.4(2.3) 2(0.3–3.5) 2.0(2.7) 0(0–4) 25.3(3),p < 0.001 1 < 2; 1 < 3; 1 < 4
Symptom Score 4.3(2.4) 5(3.2–5) 1.9(1.8) 2(0–3.4) 0.9(1.2) 0(0–2) 0.7(1.4) 0(0–1) 32.9(3),p < 0.001 1 < 2; 1 < 3; 1 < 4
SD, standard deviation; SIR, semi-Interquartile Range; df, degree of freedom.
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treatments. This included discomfort due to excess non-
evaporated coolant dripping out of the nose (two), dis-
comfort/pain related to nasal catheter placement (two),
in one case together with transient hypertension, and
one episode of mild epistaxis (blood streaked nasal mu-
cous). In four of these episodes, despite early termin-
ation, the patients still recieved a treatment benefit. Out
of those patients who terminated early, 3 out of the 5
stated that they would use the device again if it was
available within the NHS.
All side effects were mild and subsided spontaneously,
without need for further treatment. No treatment related
side effects were reported at the 24 hour follow up call.
Discussion
This pilot trial demonstrated a significant therapeutic
effect with intranasal evaporative cooling as an acute
treatment for migraine. The study findings suggest thatFigure 4 Pain and discomfort associated with intra-nasal cooling. VASintranasal cooling rapidly relieves pain as well as migraine-
associated symptoms.
Migraine is considered to be a neurovascular disorder.
Even though the event initiating the actual migraine at-
tack remain unknown, activation of the trigeminovascu-
lar system is considered to play an essential role in
pathophysiology of the migraine attack [23]. We believe
that the vascular anatomy of the nasal cavity allows
transfer of venous blood from paranasal mucous mem-
branes to the dura mater and may transmit temperature
changes via both direct conductive mechanisms that do
not rely on spontaneous circulation as well as indirect
haematogenous mechanisms via dural vessels. This may
influence the temperature of the brain parenchyma dir-
ectly or indirectly, via brain arteries, possibly inducing
vasoconstriction, reducing blood flow and inhibiting re-
lease of inflamatory mediators. These inflammatory me-
diators play a role in increased vascular permeability and
local oedema [11,12].: 0 = No pain/Discomfort, 10 = severe pain/discomfort; RC, RhinoChill.
Table 5 Pain and discomfort associated with intranasal
cooling on the Visual Analogue Scale (VAS)
Variable N Min Max Mean Std.
deviation
RC Associated pain at 5 mins 20 .00 8.00 2.25 2.95
RC Associated pain at 10 mins 19 .00 8.00 1.94 2.80
RC Associated pain at 15 mins 13 .00 7.00 1.61 2.66
RC Associated pain at 20 mins 8 .00 7.00 2.25 3.15
RC Associated discomfort at 5 mins 20 .00 10.00 5.25 2.65
RC Associated discomfort at 10 mins 19 .00 8.00 3.84 2.29
RC Associated discomfort at 15 mins 13 .00 8.00 3.50 2.27
RC Associated discomfort at 20 mins 8 .00 8.00 3.44 2.58
RC, RhinoChill; Min, Minimum value recorded; Max, Maximum value recorded;
Std. Deviation, Standard Deviation; VAS: 0 = no pain/no discomfort, 10 = severe
pain/discomfort.
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and enzymatic activity, albeit it is not clear what the
mode of action is which impacts on the release of local
neuropeptides.
Recent studies indicate that Transient Receptor Poten-
tial (TRP) channels may have a role in the headache andFigure 5 Mean arterial pressure and depth of insertion of nasal cathepain genesis due to their response to stimuli such as
temperature, changes in osmolality, pH and environ-
mental products [18,24,25]. TRP channels may represent
novel targets for headache therapeutics. Out of the six
subfamilies of TRP channels, Transient Receptor Poten-
tial V1, M8, A1 (TRPV1, TRPM8, TRPA1) seems to be
the ones researchers believe are expressed on the exter-
nal nociceptors, which could result in activation of noci-
ceptors and produce pain [26-28].
Intranasal cooling might have had a stimulating effect
on TRP channels, likely in antagonistic inhibitory way
for TRPV1, TRPA1, and possibly as an agonist on TRPM8
channel.
Other inhibitory factors such as differential alteration
of nerve conduction velocities mediated its effect via
gate control mechanism, might have played a part in the
process leading to the pain and symptoms termination.
A vasoconstrictor response of brain vessels to 100% oxy-
gen inhalation has been known for decades. In patients
with acute hemispheric infarction, regional vasoconstrictor
responsiveness to 100% oxygen inhalation was decreased
[29]. Whilst it is clear that oxygen is a very useful therapy
in cluster headaches, there is some evidence of the benefitter. Tx, Treatment; MAP, Mean Arterial Pressure.
Table 6 Adverse events
Adverse event during treatment Number of
episodes
Nasal Discomfort/Pain due to catheter 3
Nasal discomfort due to cooling 2
Hypertension 2
Mild epistaxis 1
Discomfort due to excess fluid dripping from nose 2
Adverse Event Following Treatment
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but the benefit of normobaric oxygen therapy in migraine
remains rather controversial [30].
The coolant, a non-ozone depleting six chain perflurocar-
bon, perfluorohexane (PFH), does not oxidize or hydrolyze
and cannot undergo biological oxidation-reduction reactions
to form reactive aldehydes, acid fluorides, radicals, or
other acids. Since it does not react directly with biological
tissue, and cannot form reactive metabolites or react with
receptors, or channels, so we anticipate PFH doesn’t have
any direct benefit in the migraine treatment, other than
acting as a coolant.
The therapeutic effect of intranasal evaporative cooling
was not diminished by the shallow insertion of catheter,
nor impacted by premature termination of the treatment.
With respect to the duration of the treatment and depth of
the nasal catheter insertion, further evaluation is required
involving a study with a larger number of participants.
Our trial highlighted the importance of a non-
pharmacological approach. Further trials to examine a
non-pharmacological approach are warranted.
We acknowledge that a major limitation of this study
is the small sample size and lack of a control group. A
further randomized, placebo controlled trial is therefore
essential to confirm the effectiveness of intranasal cool-
ing as an acute treatment in migraine.
Conclusion
In conclusion we found that there is a therapeutic effect
from intranasal evaporative cooling in patients with mi-
graine, giving benefit on headache as well as accompany-
ing migraine symptoms to 13 patients (87%) at 2 hours
post-treatment; even though this was an in-hospital
treatment with a device and thus the placebo effect may
be pronounced.This study did not reveal any significant or severe side
effects. Nasal cooling was well tolerated by majority of
the participants and we found that nasal cooling was
safe to use for this indication.
While these results are promising, a randomized pla-
cebo controlled, double blinded trial is needed to con-
firm the efficacy of intranasal cooling as an acute
treatment in migraine. Further studies will also be re-
quired to clarify the mode of action of this therapeutic
intervention.
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